
    
      The primary objective of this phase II trial is to estimate the rate of complete pathologic
      response as determined by surgical resection or post treatment endoscopy (for patients not
      undergoing resection) for the treatment regimen being tested. With a total accrual of 28
      evaluable patients.
    
  